logo

With the rapid implementation of ‘targeted’ therapies, kidney cancer has entered a new era where old paradigms are being challenged, and new ones can be explored. The idea of deliv[...]
 Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study Abstract Objective To evaluate the ability of neoadjuvant axitinib to redu[...]
Every week the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full arti[...]
Chemotherapy, the dominant therapeutic approach to the treatment of a wide variety of cancers, is intrinsically inefficient because its drug delivery is non-specific. This leads to[...]